TSI Investor Profile: Inmed

Company: Inmed

Symbol: CSE: IN | OTCQB: IMLFF

Country: Canada
Sector: Healthcare
Industry: Biotech
Established: 2012

Inmed

Featured Video

Company Brief

Proprietary Drug/Disease Targeting Tool

InMed’s proprietary bioinformatics algorithm assesses the different active sites on cannabinoids and screens them against approved drug structures, disease site receptors, genetic profiles of diseases, and the involvement of proteins and chemical metabolites in disease pathways. This program then selects specific cannabinoids (or combinations thereof) that might play a role in regulating diseases.

Summary

Fiscal Year-End: December
License Renewal Month: October 2017
Licenses: 1
Licensed Capacity: N/A
Number of Patients: N/A
Headquarters: Vancouver, BC

Financials (pro forma 09/30)

Cash on hand: $2.7mm
Fixed Investment: $5.72mm
Shareholders’ Equity: $17.8mm
Revenues – Last Quarter: N/A
Adj. Gross Margin: N/A
EPS: N/A

Capital Structure (07/31/17)

Last Financing: xx mm shares at $0.xx
Basic Shares: 97.20mm
Warrants: 14.1mm
Options: 14.7mm
Diluted Shares: 121.9mm

 

Highlights

 

  • Broad portfolio of assets in dermatology, ocular diseases, additional indications and cannabinoid biosynthesis
  • Positioning to achieve value-driving, near-term milestones with limited investment: 
  • Experienced team capable of building value in biopharmaceuticals

 

Growth Strategy

 

  • Lead drug candidate in an orphan paediatric disease with high unmet medical need; final formulation development, toxicology and Ph1-2a clinical trials targeted for completion within 24 months from financing
  • Biosynthesis of cannabinoids aimed to be commercial ready within 24 months from financing
  • Active discussions to license production to U.S. operators

 

Differentiators

 

  • Bioinformatics Database Proprietary computer-based drug/disease target screening tool
  • Biosynthesis Proprietary cannabinoid manufacturing system
  • Drug Development Pipeline Expedited drug development timelines, conservative clinical budget targeting high unmet medical conditions utilizing disease-specific formulations:
  • INM-750 for Epidermolysis Bullosa – An orphan paediatric disease characterized by extremely fragile skin with no current approved therapies. Potential global market revenues of ~US$1B.
  • INM-085 for Glaucoma – A serious eye disease with a global market of >US$5B

Interview

Drug Development

R&D Timelines

 


 


Strong Management Team


Eric A. Adams CEO + President - 25+ years’ experience in global biopharmaceutical business development, Sales, Marketing, M&A with enGene, QLT, Advanced Tissue Sciences, Abbott Laboratories, Fresenius AG

Dr. Sazzad Hossain Chief Scientific Officer, PhD, M.Sc. - 20+ years of academic/industry experience in drug discovery and product development at Xenon Pharmaceuticals, targeting pain, inflammation and cardiovascular diseases; and Canada’s National Research Council

Dr. Ado Muhammad Chief Medical Officer, MD, DPM, MFPM - Former Associate Medical Director at GW Pharmaceuticals specializing in the development of cannabinoid-based prescription medicines

Jeff Charpentier Chief Financial Officer + Corporate Secretary - 25+ years’ experience in biotech and technology companies including Lifebank Corp., Inex Pharmaceuticals, and Chromos Molecular Systems Inc.

Alexandra Mancini Sr. Vice President, Clinical and Regulatory Affairs, M.Sc. - 30 years’ global biopharmaceutical R&D experience with Sirius Genomics, Inex Pharmaceuticals, and QLT Inc.

 


InMed Pharmaceuticals Announces the Closing of C$14.95 Million Bought Deal Financing including Full Exercise of Underwriter's Over-Allotment Option

InMed Pharmaceuticals Inc. (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary biosynthesis platform technology to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today announced that it has closed the "bought deal" financing originally announced on June 12, 2018, and that the over-allotment option of the underwriter, Eight Capital, has been exercised in full. The total gross proceeds raised by the Company in the Financing were C$14.95 million.

InMed Reports Third Quarter Fiscal 2018 Financial Results and Provides Business Update

InMed Pharmaceuticals Inc. (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary bioinformatics and biosynthesis platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today reported financial results for the three and nine months ended March 31, 2018, which is the Company's third quarter of fiscal year 2018 ("3Q18").

OTC Markets Group Welcomes InMed Pharmaceuticals Inc. to OTCQX

OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced InMed Pharmaceuticals Inc. (TSX: IN; OTCQX: IMLFF), a cannabinoid-focused biopharmaceutical company, has qualified to trade on the OTCQX® Best Market. InMed Pharmaceuticals upgraded to OTCQX from the OTCQB® Venture Market.

INMED TO PRESENT AT CANACCORD GENUITY CONFERENCE

InMed Pharmaceuticals, Inc. (CSE:IN; OTCQB: IMLFF), a biopharmaceutical company specializing in the research and development of novel, cannabinoid-based drug therapies, announced today it will present at Canaccord Genuity's 2nd Annual Cannabis Investor Day taking place at The Fairmont Waterfront Hotel in Vancouver, BC, on Wednesday, January 24, 2018.

Biotech Market Banking on Big Cannabis Returns

Backed by mounting scientific data on the curative effects of CBDs, specialty biotech companies like InMed Pharmaceuticals, Inc. (CSE: IN) (OTC: IMLFF) have the opportunity to capitalize on the explosive growth expected in the cannabis-derived pharmaceutical market.

INMED CLOSES OVER-SUBSCRIBED C$9.4 MILLION FINANCING

InMed Pharmaceuticals, Inc. (CSE:IN; OTCQB: IMLFF), has closed its previously announced non-brokered private placement for gross proceeds of C$9.4 Million through the issuance of 13,428,571 units, with terms as previously announced on December 18, 2017.